Emerging Targets in Non-Small Cell Lung Cancer

被引：11

作者：

Liu, Louisa ^{[1
]}

Soler, Joshua ^{[2
]}

Reckamp, Karen L. ^{[1
]}

Sankar, Kamya ^{[1
]}

机构：

[1] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA

[2] Univ Calif Riverside, Riverside Sch Med, Riverside, CA 92521 USA

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2024年 / 25卷 / 18期

关键词：

non-small cell lung cancer; targeted therapies; oncogene driver; novel combinatorial approaches; ARGININE METHYLTRANSFERASE 5; SOLID TUMORS; PHASE-I; OPEN-LABEL; EXPRESSION; INHIBITOR; BRAF; PRMT5; KRAS; EFFICACY;

D O I：

10.3390/ijms251810046

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Lung cancer is responsible for a high burden of disease globally. Over the last two decades, the discovery of targetable oncogenic genomic alterations has revolutionized the treatment landscape for early-stage and advanced non-small cell lung cancer (NSCLC). New molecular drivers continue to emerge as promising therapeutic targets, including KRAS non-G12C, RAF/MEK, HER3, Nectin-4, folate receptor alpha, ITGB6, and PRMT5. In this review, we summarize the emerging molecular targets with a potential clinical impact in advanced NSCLC, elaborating on their clinical characteristics and specific mechanisms and molecular pathways for which targeted treatments are currently available. Additionally, we present an aggregate of ongoing clinical trials investigating the available treatment options targeting such alterations, in addition to their current recruitment status and preliminary efficacy data. These advancements may guide further research endeavors and inform future treatment strategies to improve the management of and transform outcomes for patients with advanced NSCLC.

引用

页数：23

共 169 条

[1] Nuclear Cyclin D1/CDK4 Kinase Regulates CUL4 Expression and Triggers Neoplastic Growth via Activation of the PRMT5 Methyltransferase [J].

Aggarwal, Priya ;

Vaites, Laura Pontano ;

Kim, Jong Kyong ;

Mellert, Hestia ;

Gurung, Buddha ;

Nakagawa, Hiroshi ;

Herlyn, Meenhard ;

Hua, Xianxin ;

Rustgi, Anil K. ;

McMahon, Steven B. ;

Diehl, J. Alan .

CANCER CELL, 2010, 18 (04) :329-340

[2] PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study. [J].

Ahnert, Jordi Rodon ;

Perez, Cesar Augusto ;

Wong, Kit Man ;

Maitland, Michael L. ;

Tsai, Frank ;

Berlin, Jordan ;

Liao, Kai Hsin ;

Wang, I-Ming ;

Markovtsova, Lada ;

Jacobs, Ira A. ;

Cavazos, Nora ;

Li, Meng ;

Tolcher, Anthony W. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[3] Targeting the TGFβ signalling pathway in disease [J].

Akhurst, Rosemary J. ;

Hata, Akiko .

NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (10) :790-811

[4] Resiliency and Vulnerability in the HER2-HER3 Tumorigenic Driver [J].

Amin, Dhara N. ;

Sergina, Natalia ;

Ahuja, Deepika ;

McMahon, Martin ;

Blair, Jimmy A. ;

Wang, Donghui ;

Hann, Byron ;

Koch, Kevin M. ;

Shokat, Kevan M. ;

Moasser, Mark M. .

SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (16) :16ra7

[5] Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [J].

Arbour, K. C. ;

Punekar, S. ;

Garrido-Laguna, I. ;

Hong, D. S. ;

Wolpin, B. ;

Pelster, M. S. ;

Barve, M. ;

Starodub, A. ;

Sommerhalder, D. ;

Chang, S. ;

Zhang, Y. ;

Salman, Z. ;

Wang, X. ;

Gustafson, C. ;

Spira, A. I. .

ANNALS OF ONCOLOGY, 2023, 34 :S458-S458

[6] 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study [J].

Ascierto, Paolo A. ;

Dreno, Brigitte ;

Larkin, James ;

Ribas, Antoni ;

Liszkay, Gabriella ;

Maio, Michele ;

Mandala, Mario ;

Demidov, Lev ;

Stroyakovskiy, Daniil ;

Thomas, Luc ;

de la Cruz-Merino, Luis ;

Atkinson, Victoria ;

Dutriaux, Caroline ;

Garbe, Claus ;

Hsu, Jessie ;

Jones, Surai ;

Li, Haocheng ;

McKenna, Edward ;

Voulgari, Athina ;

McArthur, Grant A. .

CLINICAL CANCER RESEARCH, 2021, 27 (19) :5225-5235

[7]

Awad M.M., 2023, Mol. Cancer Ther, V22, pC026, DOI [10.1158/1535-7163.TARG-23-C026, DOI 10.1158/1535-7163.TARG-23-C026]

[8] Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 [J].

Baselga, Jose ;

Swain, Sandra M. .

NATURE REVIEWS CANCER, 2009, 9 (07) :463-475

[9]

Beck JTT, 2023, J CLIN ONCOL, V41

[10] β6-integrin serves as a novel serum tumor marker for colorectal carcinoma [J].

Bengs, Susan ;

Becker, Eugenia ;

Busenhart, Philipp ;

Spalinger, Marianne R. ;

Raselli, Tina ;

Kasper, Stephanie ;

Lang, Silvia ;

Atrott, Kirstin ;

Mamie, Celine ;

Vavricka, Stephan R. ;

Von Boehmer, Lotta ;

Knuth, Alexander ;

Tuomisto, Anne ;

Makinen, Markus J. ;

Hruz, Petr ;

Turina, Matthias ;

Rickenbacher, Andreas ;

Petrowsky, Henrik ;

Weber, Achim ;

Frei, Pascal ;

Halama, Marcel ;

Jenkins, Gisli ;

Sheppard, Dean ;

Croner, Roland S. ;

Christoph, Jan ;

Britzen-Laurent, Nathalie ;

Naschberger, Elisabeth ;

Schellerer, Vera ;

Stuerzl, Michael ;

Fried, Michael ;

Rogler, Gerhard ;

Scharl, Michael .

INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (03) :678-685

← 1 2 3 4 5 6 7 8 9 10 →